# AMIODARONE

This document should be read in conjunction with this **DISCLAIMER**

---

## Presentation

| Presentation | Tablet: 200mg  
| | Ampoule: 150mg/3mL |

## Dose

### Cardiac Arrest

**Route:** IV / Intraosseous

- **Emergency Dose:** 300mg IV or Intraosseous as a bolus
- **Loading Dose:** 5mg/kg IV infuse over 20 minutes to 2 hours
- **Maintenance Dose:** 15-20mg/kg IV infuse over 24 hours; overlap oral and IV treatment by 2 days

### Ventricular Arrhythmias

**Route:** IV

- 150mg over 10 min; repeat if necessary

This may be followed by infusion 1mg/min for 6 hours, followed by 0.5mg/min. Total dose over 24 hours should not exceed 2.2g

### Supraventricular Arrhythmias

**Route:** IV Infusion

- 300mg over 1 hour followed by 1mg/minute for 6 hours.

**Maintenance**

**Route:** Oral

- 100 - 200mg daily (up to 400mg daily may be required)

## Administration

**IV / Intraosseous injection**

Dilute 150 - 300mg in 10 to 20mL Glucose 5% and inject over 1 to 2 minutes. Be aware of hypotension and circulatory collapse with this method.
| **IV Infusion** |  
| **Step 1 Dilution:** Dilute in 100mL Glucose 5%  
| **Administration:** Administer using a volumetric pump via a central line or large intravenous cannula in large vein with cardiac monitoring  

| **Pregnancy** |  
| Amiodarone should not be given to pregnant mothers unless critically required  
| **1st Trimester:** Consider alternative  
| **2nd Trimester:** Monitoring required  
| **3rd Trimester:** Monitoring required  
| Thyroid function of newborn should be assessed  
| Contact OMIS for further information  

| **Breastfeeding** |  
| Monitoring required  
| Infant should be closely monitored for cardiovascular and thyroid function  
| Contact OMIS for further information  

| **Monitoring** |  
| ECG, Blood pressure, Vital signs  

| **Clinical guidelines and policies** |  
| Emergency Procedures: Recognising and Responding to Clinical Deterioration  
| Adult Resuscitation Drug Protocol: Amiodarone  
| WNHS Policy: Administration of parenteral drugs  
| Labelling of Injectable Medicines and Fluids  
| High Risk Medication List  

| **References** |  
### Keywords:
Amiodarone, Cardiac Arrest, Arrhythmia

<table>
<thead>
<tr>
<th>Publishing:</th>
<th>✅ Intranet  ❌ Internet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document owner:</td>
<td>Chief Pharmacist</td>
</tr>
<tr>
<td>Author / Reviewer:</td>
<td>Pharmacy Department</td>
</tr>
<tr>
<td>Date first issued:</td>
<td>Version: 3.0</td>
</tr>
<tr>
<td>Last reviewed:</td>
<td>July 2017  Next review date: July 2020</td>
</tr>
<tr>
<td>Endorsed by:</td>
<td>Medicine and Therapeutic Committee  Date:</td>
</tr>
</tbody>
</table>

### Standards Applicable:
NSQHS Standards:
1. 🔴 Clinical Care is Guided by Current Best Practice
4. 🟢 Medication Safety

**Printed or personally saved electronic copies of this document are considered uncontrolled.**
**Access the current version from the WNHS website.**

© Department of Health Western Australia 2017